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Abstract.  The urokinase plasminogen activator recep- 
tor (uPAR), a glycosylphosphatidylinositol-linked gly- 
coprotein, plays a central role in the regulation of 
pericellular proteolysis and participates in events lead- 
ing to cell activation.  Here, we demonstrate that 
uPAR, on a human melanoma cell line,  is localized in 
caveolae, flask-shaped microinvaginations  of the 
plasma membrane found in a variety of cell types. In- 
direct immunofluorescence with anti-uPAR antibodies 
on the melanoma cells showed a punctated staining 
pattern that accumulated to stretches along sides of 
cell-cell contact and membrane ruffles, uPAR colocal- 
ized with caveolin, a characteristic protein in the coat 
of caveolae, as demonstrated by double staining with 
specific antibodies.  Further,  uPAR could be directly 
localized in caveolae by in vivo immunoelectron 
microscopy. Both uPAR and its ligand,  uPA, were 
present in caveolae enriched low density Triton X-100 
insoluble complexes, as shown by immunoblotting. 
From such complexes, caveolin could be coprecipi- 
tated with uPAR-specific antibodies suggesting a close 
spatial association between uPAR and caveolin that 
might have implications for the signal transduction 
mediated by uPAR. Further,  functional studies indi- 
cated that the localization of uPAR and its ligand in 
caveolae enhances pericellular plasminogen activation, 
since treatment of the ceils with drugs that interfere 
with the structural integrity of caveolae, such as nysta- 
tin,  markedly reduced cell surface plasmin generation. 
Thus,  caveolae promote efficient cell surface plas- 
minogen activation by clustering uPAR, uPA, and pos- 
sibly other protease receptors in one membrane 
compartment. 
T  IGrITLV regulated  extraceUular  proteolytic  systems 
are involved in the dissolution  of extracellular  matrix 
and in the modulation  of cellular interactions  in such 
processes as leukocyte recruitment to sites of inflammation 
or tumor cell invasion and metastasis.  For example,  plas- 
minogen activators  specifically convert the latent ubiquitous 
zymogen plasminogen  into plasmin,  a protease which can 
degrade a wide spectrum of glycoproteins.  Plasmin genera- 
tion,  particularly through  the urokinase-type plasminogen 
activator  (uPA)  t,  contributes  significantly  to  pericellular 
proteolysis and is likely modulated by cell surface receptors 
(for review see Ellis et al.,  1992; Blasi,  1993). 
A  specific  uPA-receptor  (uPAR)  has  been  detected on 
many different cell types including  monocytes (Stoppeli et 
al.,  1985;  Min et al.,  1992),  neutrophils  (Plesner et al., 
1994), endothelial  cells (Miles et al.,  1988; Pepper et al., 
Please address all correspondence to Dr. B. M. Mueller, Department of Im- 
munology,  The Scripps Research  Institute,  10666 N.  Torrey  Pines Rd., 
IMMI3, La Jolla, CA 92037. Tel.:  (619) 554-8124.  Fax:  (619) 554-6705. 
1.  Abbreviations  used  in  this  paper:  DTSSP, [3,3'-dithiobis  (sulfosuc- 
cinimidylpropionate)]; GPI,  glycosylphosphatidylinositol;  OGP,  n-octyl 
~-D-glucopyranoside;  uPA, urokinase-type  plasminogen  activator; uPAR, 
uPA receptor. 
1993), keratinocytes  (McNeill and Jensen, 1990; Del Rosso 
et al.,  1990),  as well as various  tumor cell lines  (Stoppeli 
et al.,  1986; Boyd et al.,  1988; Hollas et al.,  1992; Moha- 
nam et al., 1993). The biochemical characterization  of uPAR 
identified a single chain, 55-60-kD glycoprotein  (Nielsen et 
al.,  1988) that  is  anchored  in  the  cell  membrane  by  a 
glycosylphosphatidylinositol  (GPI)  moiety  (Ploug  et  al., 
1991). Primarily, uPAR is thought to enhance and direct uPA 
proteolytic activity (Ellis  et al.,  1989;  Estreicher  et al., 
1990; Manchanda and Schwartz,  1991). However, uPAR has 
also been implicated in mediating the internalization  of uPA- 
plasminogen  activator  inhibitor  complexes  (Olson  et al., 
1992; Li et al., 1994). Moreover, the binding of catalytically 
active or inactive uPA to uPAR can stimulate cell prolifera- 
tion (Kirchheimer  et al., 1989; Rabbani et al., 1990), as well 
as chemotactic and  haptotactic cell migration  (Odekon et 
al.,  1992;  Gyetko et al.,  1994;  Stahl  and  Mueller,  1994; 
Busso et al.,  1994).  Together, these findings demonstrate 
that  the GPI-linked  uPAR functions  not merely as a uPA- 
binding protein,  but is also involved in the regulation of cell- 
mediated proteolysis and cell activation. 
GPI-linked  proteins  have  been  described  to  cluster  in 
plasma membrane conformations known as caveolae. Caveo- 
lae were originally described as membrane invaginations on 
the cell surface that were later found to have a characteristic 
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1992). The folate receptor (Rothberg et ai., 1990) and other 
GPI-linked proteins (Ying et al., 1992; Keller et al., 1992) 
were demonstrated by immunocytochemistry  to be localized 
in caveolae. Cholesterol and glycolipid rich low density Tri- 
ton X-100  insoluble complexes isolated from cell lysates 
(Brown and Rose, 1992; Sargiacomo et al., 1993) contain a 
membrane fraction highly enriched for caveolae. Both cav- 
eolin and GPI-linked proteins have been identified biochemi- 
caily in such detergent insoluble complexes isolated from 
different cell types, including MDCK cells (Sargiacomo et 
al.,  1993),  endothelial cells from human lung (Lisanti et 
al.,  1994),  and smooth muscle cells from chicken gizzard 
(Chang et al.,  1994). 
We reasoned that the subcellular distribution of  uPAR may 
be directed by its GPI-anchor resulting in a  clustering of 
uPAR in caveolae. To study the localization of uPAR, we 
used a highly metastatic human melanoma cell line that ex- 
presses very high levels of uPAR (Stahl and Mueller, 1994). 
Here, we present three lines of evidence demonstrating that 
the subcellular localization of uPAR in these melanoma cells 
is indeed in caveolae: (a) uPAR, uPA, and caveolin are exclu- 
sively found in the low density detergent insoluble fraction 
of cell lysates; (b) uPAR colocalizes with caveolin when ana- 
lyzed by indirect immunofluorescence; and (c)  the ultra- 
structural localization of uPAR is largely confined to small, 
nonclathrin-coated invaginations of the plasma membrane. 
The finding that uPAR is localized in caveolae suggests that 
caveolae may serve as a specialized compartment for pericel- 
lular plasminogen activation.  In support of this idea,  we 
could demonstrate that the pretreatment of melanoma cells 
with drugs that interfere with the structural integrity of cav- 
eolae markedly reduced cell surface plasminogen activation. 
Materials and Methods 
Antibodies 
The monoclonal mouse anti-human uPAR antibody mAb 3936 (IgG2a) and 
polyclonal rabbit anti-human uPAR antibodies, 399R, and polyclonal rabbit 
anti-human uPA antibodies were kindly provided by Dr.  Richard Hart, 
American Diagnostica (Greenwich, CT).  An inhibiting anti-uPA mouse 
monoclonal antibody was purchased from York Biologicals International 
(Stony Brook, NY). Normal mouse and rabbit sera were purchased from 
Dako  (Carpcnteria,  CA).  A  monoclonal  mouse  anti-22  kD  RSV-SRC 
substrate  (caveolin)  antibody  was  purchased  from  ICN  Biomedicals, 
Inc. (Costa Mesa, CA). Mouse monoclonal anti-annexin heavy and light 
chain antibodies were purchased from Transduction Laboratories (Lexing- 
ton, KY). 
Tumor Cell Line 
The human melanoma cell line M24met has been described previously 
(Mueller et al., 1991). M24met cells were routinely cultured in RPMI 1640 
supplemented with 10 % FBS and 2 mM glutamine (Whittaker Bioproducts, 
Walkersville,  MD).  Cells were passaged using versene, 0.5 mM EDTA, 
0.15 M NaCI, and 0.02 M  Hepes. 
lmmunofluorescence Staining and Laser Scanning 
Confacal Microscopy 
Cells were grown on gelatin-coated coverslips to the desired cell density; 
washed once with HBSS (with 1 mM Ca  2+ and Mg  2+) and fixed with 4% 
fresh paraformaldehyde for 30 rain at room temperature (RT).  Results of 
preliminary experiments indicated that cells fixed in 4% paraformaldehyde, 
0.5% glutaraldehyde showed no diffferonce in their staining patterns when 
compared with cells fixed in 4% paraformaldehyde only.  Cells were per- 
meabilixed for 5 min on ice with 0.05%  saponin in HBSS and blocked with 
5% BSA in HBSS for 30 min on ice. These permeabilized ceils were in- 
cubated  with  primary  antibodies  (rabbit  anti-uPAR  and  mouse  anti- 
caveolin) 1 h on ice, washed three times with I-IBSS and incubated for 40-60 
rain  on  ice  with  the  secondary  antibody  (rhodamine-conjugated goat- 
anti-mouse IgG and FrI~-conjugated goat-anti-rabbit IgG; TAGO, Burlin- 
game, CA). For the staining of F-actin, 5 t~l of a 6.6-#M rhodamine phal- 
loidin (Molecular Probes, Eugene, OR) stock solution were used.  Cells 
were washed three times with HBSS and once in distilled water. Slides were 
mounted with Slow Fade (Molecular Probes, Eugene, OR) and sealed with 
nail polish. The double-labeled specimen were examined with a (MRC 600) 
laser scanning confocal microscope equipped with an argon/krypton laser 
(),l  -- 488 nm, blue line for FITC; )~2  =  568 nm, yellow line for rhoda- 
mine) (BioRad Labs, Hercules, CA). The recorded images were merged to 
illustrate the colocalization of uPAR and caveolin to the membrane. The 
gain and black levels were set to ensure that the collected images reflected 
the full range of grey level values from black (0 pixel intensity) to maximal 
white (255  pixel intensity). Optical  sections of immunolabeled samples 
were examined at high magnification (1,000, Planapo 63×,  NA  1.4, with 
oil). A section plane was collected at true focus using Kalman averaging 
at an optical zoom setting of one or more. 
Electron Microscopy 
M24met cells were seeded in 24-well plates and incubated on ice with the 
polyclonal anti-uPAR antibody. After three PBS washes, bound antibody 
was detected with goat-anti-rabbit IgG 5-nm gold conjugates. After wash- 
ing the cells, they were fixed in modified Karnovsky's fixative (2% parafor- 
maldehyde, 1.5 % glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4) for 2 h 
at 4°C and postfixed in 1% OsO4 in the same buffer for 1 h at RT. The fixed 
cells were stained in 50% saturated aqueous uranyl acetate solution for 1 h, 
dehydrated in graded ethanol and flat embedded in 812 epoxy resin (TAAB 
Laboratories Equipment, Reading, England). Thin sections were cut on an 
LKB Ultrotome IH, mounted on a copper grid, stained in uranyl acetate 
and lead citrate, and viewed with a Hitachi HU 12A electron microscope 
at 75 kV acceleration. 
Isolation of ~ton-Insoluble Complexes by Sucrose 
Gradient Centrifugation 
Low density, Triton-insoluble complexes were prepared, as described (Sar- 
giacomo et al.,  1993).  Briefly,  between 6-10  x  107 M24met cells were 
harvested with versene and lysed in 2 ml Mes-buffered saline (MBS; 25 mM 
Mes, pH 6.5, 0.15 M NaCI) 1% Triton X-100 with 10 strokes of a Dounce 
homogenizer. The lysates were adjusted to 40% sucrose and overlaid with 
10 ml of a  30-5 % linear sucrose gradient. The lysates were centrifuged 
overnight at 40,000 rpm (190,000 g) in a SW41 rotor (Beckman Instrs., Palo 
Alto, CA). Gradients were harvested and fractionated with fraction  1-6 
spanning 5-30% sucrose and fraction 7 containing 40% sucrose. Fraction 
8 was the pellet solubilized by boiling in 200 ~1 10% SDS for 5 rain. The 
protein content in each fraction was measured using the BCA assay (Pierce, 
Rockford, IL). Equal amounts of protein ('~10 ~g per lane) were separated 
on 5-15 % SDS gradient gels and specific proteins were detected by Western 
blotting. The distribution of the blotted protein over the gradient fractions 
was quantified by laser densitometry on a Personal Densitometer (Molecu- 
lar Dynamics, Sunnyvale, CA) using local background correction. 
Sequential Extraction and Cross-linking 
Sequential extraction and cross-linking were performed essentially, as de- 
scribed (Lisanti et al., 1993).  A monolayer of ,~10  ×  106 cells was washed 
briefly with PBS, and then extracted for 30 rain on ice with 10 ml of e.xtrac- 
tion buffer A  (MBS, pH 6.5,  1% Triton X-100;  1 mM PMSF;  10 t~g/ml 
aprotinin;  1 mM sodium ortho vanadate).  The extraction buffer was re- 
moved and 10 ml of a I mg/ml solution of [3,Y-dithiobis(sulfosuccinimidyl- 
propionate)] (DTSSP;  Pierce, Rockford, IL)  in extraction buffer A  was 
added to the ceils. Cross-linking of the Triton X-100 insoluble complexes 
was carried out for 30 rain on ice without agitation. After removing the 
cross-linking solution a second round of extraction was performed in 10 ml 
of extraction buffer B (TBS, pH 7.8; 60 mM n-octyl B-o-glucopyranoside 
(OGP);  1 mM PMSF; 10 t~g/ml aprotinin; 1 mM sodium ortho vanadate) 
or extraction buffer  C (10 mid Tris, pH 7.8, 0.15 M NaCl, 3 % Triton X-114); 
1 mM PMSF; 10/~g/ml aprotinln; 1 mM sodium ortho vanadate). For this 
second extraction the cells were agitated on an orbital shaker for 30 rain 
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Triton X-I14 extracts were subjected to temperature induced phase separa- 
tion, as described (Behrendt et al.,  1993). 
Surface Biotinylation 
Surface biotinylation with NHS-LC-biotin (Pierce) was done according to 
the manufacturer's suggestions.  Briefly, 5  X  106 M24met cells were har- 
vested  with  versene  and  washed  twice  in  PBS.  The  cells  were  then 
resuspended in 5 ml PBS containing 100 t~l ofa NHS-LC-biotin stock solu- 
tion (10 mg/ml) and incubated on a rotator for 60 rain at room temperature. 
Cells were washed twice in PBS and resnspended in 1 ml NP-40 lysis buffer 
(10 mM Tris/HCl, pH 7.4; 150 mM NaCI;  1% NP-40;  1 mM EDTA; 1 mM 
PMSF; 10 pg/mi Apvotinin). Lysates were precleared and subjected to irn- 
munoprecipitation. 
Immunoprecipitation and Western Blotting 
Immunoprecipitation of extracts from sequential  extractions was preceded 
by preclearing of lysates  with Pansorbin (Calbiochem, La Joila, CA) and 
incubated for 1 h with 10 t~g of the appropriate antibody that was previously 
bound to 50 td of a slurry of protein A-Sepbarose. Immunoprecipitates 
were washed four times with the buffer used for the second extraction (see 
Sequential Extraction) and three times with PBS, 0.1% Tween 20 (PBS-T) 
and finally boiled for 3 rain in 20 ~,l of reducing Laemmli buffer. Proteins 
were separated on a 5-15 % denaturing polyacrylamide  (Protogel,  National 
Diagnostics,  Atlanta, GA) gradient gel and transferred to a nitrocellulose 
membrane (BioBlot-NC, Costal Cambridge, MA) using a semidry blotting 
apparatus (0.8 mA/cm  2 membrane; transfer buffer containing 20 mM Tris, 
150 mM glycine,  0.1% SDS,  20% methanol), Membranes were blocked 
overnight in PBS-T containing 5 % nonfat dry milk powder. The primary an- 
tibodies used for Western blotting were diluted in PBS-T containing t% 
nonfat dry milk powder to a concentration of 2 ~g/ml and incubated with 
the membranes for 1 h. Excess antibody was removed by three washes with 
PBS-T. The specifically bound primary antibody was detected by species- 
specific  goat antibodies conjugated  to horseradish peroxidase (Bio-Rad 
Labs). The membranes were incubated with the secondary antibody for 30 
rain and washed five times in PBS-T. Secondary antibodies were visualized 
with an ECL kit (Amersham Corp., Arlington Heights,  IL) following the 
manufacturer's instructions. 
Piasminogen Activation Assays 
M24met cells,  5  x  lit per well, were seeded  into 96-well plates and in- 
cubated overnight  at 370C. The cells were rinsed with RPMI without phenol 
red and groups of eight wells v~re either treated with nystatin, filipin, PMA 
(all from Sigma Chem. Co., St.  Louis, MO), or with inhibiting anti-uPA 
antibodies for 1 h. Cells were rinsed again and 100 #! of a reaction mix, 
2  #M  plasminogen  (Sigma),  and  2.2  mM  of  H-D-Val-Leu-Lys-p- 
nitroanilide (S-2251) (Chromogeuix,  Franklin, OH) in RPMI without phe- 
nol red, were added to the cells.  Plasmin generation was measured every 
5  rain as  AOD4os in a  ThermoMax plate  reader  (Molecular Devices, 
Menlo Park, CA). 
Results 
uPAR Has a Punctated Localization Pattern on the 
Cell Surface and Colocalizes with Caveolin 
The cellular distribution of uPAR on M24met human mela- 
noma cells was analyzed by indirect immunofluorescence 
with a rabbit polyclonal anti-uPAR antibody. Paraformalde- 
hyde fixed, saponin permeabilized cells that were stained 
with anti-uPAR showed a staining pattern characteristic for 
a caveolar localization, i.e., a punctated pattern with clusters 
of uPAR localizing to defined regions of the plasma mem- 
brane (Fig. 1, A, D, and G). Cells fixed with paraformalde- 
hyde and glutaraldehyde demonstrated an identical staining 
pattern (data not shown). To further support our contention 
that uPAR is localized in caveolae, we used immunofluores- 
cence double labeling to demonstrate colocalization of  uPAR 
with a caveolar marker protein, caveolin. Antibodies against 
a 22-kD v-src substrate from Rous sarcoma virus-infected 
chicken fibroblasts have been shown to react specifically 
with  human  and  chicken  cavcolin  (Glenney and  Zokas, 
1989).  Thus, such a mouse monoclonal anti-caveolin anti- 
body  was  used  together  with  a  polyclonal rabbit  serum 
against uPAR for immunofluorescence double labeling of 
paraformaldehyde fixed and saponin permeabilized M24met 
cells.  Laser scanning confocal microscopy indicated that 
both antigens are localized mainly in discrete spots on the 
plasma membrane. The anti-caveolin antibody also stained, 
in some cases, a cytoplasmic compartment that likely corre- 
sponds to the Golgi network (Fig. 1 C); however, uPAR was 
strictly confined to the punctated membrane regions and 
showed a high degree of colocalization with cave.olin (Fig. 
1, B, E, and H). The colocalization of uPAR and caveolin 
was confirmed by three dimensional analysis of the cellular 
localization (data not shown) and by high resolution scan- 
ning of the corresponding membrane areas (Fig.  1 J). The 
punctated pattern of membrane regions accumulated into 
stretches along cell-cell contact sites and membrane ruffles 
(Fig. 1 K). Scans along the Z-axis of cells revealed that both 
uPAR and caveolin were mainly localized in the upper layers 
of the cell while hardly any receptor was found at the sub- 
strate contact sites. In addition, the receptor could not be 
colocalized with the actin cytoskeleton except for sites of 
membrane ruffles (Fig. 1 L). The nearly exclusive localiza- 
tion of uPAR in membrane regions clearly above the cell sub- 
strate contact sites and the distinct localization of  actin stress 
fibers and uPAR make a localization of the receptor in focal 
contact sites, as described for other cells, rather unlikely. 
Taken together, these data suggest that uPAR is localized in 
caveolae where it colocalizes with caveolin. 
The subcellular localization of uPAR was confirmed by 
immunogold electron microscopy on intact M24met cells. 
Cells were incubated on ice with anti-uPAR antibodies fol- 
lowed by secondary antibodies conjugated to 5-urn gold par- 
tides.  Anti-uPAR antibodies decorated the plasma mem- 
brane  with most of the  gold particles being localized in 
plasmalemmal caveolae (Fig. 2). Caveolae were frequently 
observed in rows along the plasma membrane. Vertical sec- 
tions showed no preference for a basal or apical labeling with 
the anti-uPAR antibody. 
uPA and uPAR Are Enriched in Low Density 
Triton-Insoluble Complexes 
To further determine whether uPAR is localized in caveolae, 
we took advantage of some distinct properties of this cell 
compartment. Caveolae are insoluble in certain detergents, 
such as 1% Triton X-100, and form glycolipid rich low den- 
sity  complexes  that  are  enriched  in  the  22-kD  caveolar 
marker protein caveolin (Sargiacomo et al.,  1993).  Insolu- 
ble,  low density complexes from M24met cells were pre- 
pared in sucrose density gradients, as described. The gra- 
dients were divided into fractions with fraction 1-6 spanning 
the 5-30 % linear sucrose gradient, fraction 7, the 40 % su- 
crose fraction, and fraction 8, the pellet. The protein concen- 
trations of the fractions were determined and equal amounts 
of total protein from each fraction were separated by SDS- 
PAGE and transferred to nitrocellulose membranes. The dis- 
tribution of uPAR over the gradient was visualized using a 
polyclonal rabbit anti-uPAR antibody. The receptor was de- 
tected as a ,~55-kD signal with 69% of the total uPAR signal 
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fluorescence  labeling  of 
M24met melanoma cells with 
antisera specific for uPAR (A, 
D, and G) and caveolin (C, F, 
and I).  Cells were fixed and 
stained,  as  described  in  the 
Materials  and  Methods  sec- 
tion.  To  demonstrate  the 
colocalization  of  uPAR  and 
caveolin  images  from  both 
fluorescence,  channels  were 
superimposed (B, E, H, J, and 
K), colocalization is indicated 
by  yellow color.  Staining of 
the cells with normal mouse 
and  rabbit  sera  as  a  control 
was  negligible.  Localization 
of F-actin was  visualized by 
staining  with  rhodamine- 
phalloidin  (1  U/slide)  and 
compared  with  the  cellular 
distribution  of  uPAR  (L). 
Bars: 5 ttm. 
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croscopy  of  M24met  mela- 
noma cells. Living cells were 
incubated  with  anti-uPAR 
specific rabbit polyclonal anti- 
body  (A-C)  or  preimmune 
rabbit  serum  (D),  as  de- 
scribed  in the  Materials  and 
Methods  section.  The recep- 
tor was localized using a goat- 
anti-rabbit  IgG  5-rim  gold 
conjugate, arrows indicate the 
location  of  anti-uPAR  anti- 
bodies.  Bar, 200 am. 
in fractions 2 and 3, corresponding to a density range from 
9.3  to  17.5%  sucrose  (Fig.  3).  An  additional  24%  of the 
receptor  specific  signal  was  detected  in  fraction 4  (17.5- 
21.7 % sucrose). Western blotting of the endogenously pro- 
duced, cell surface-bound uPA with a polyclonal rabbit anti- 
uPA antibody showed a  distribution  similar to uPAR with 
91% of the total signal in fractions 2 and 3 (Fig. 3). We com- 
pared the distribution of uPAR and its ligand in the density 
gradient with that of known markers for caveolae, namely 
caveolin and annexin II heavy and light chain. Western blot- 
ting of caveolin with a mouse monoclonal anti-caveolin anti- 
body showed that 99% of the total signal was in fractions 2 
and 3 (Fig. 3).  This finding is in accordance with previous 
reports that low density Triton X-100 insoluble complexes 
representing caveolae are enriched in the  15-20%  sucrose 
range of density gradients (Lisanti et al.,  1993).  Immuno- 
blotting with mouse monoclonal anti-annexin II heavy and 
light chain antibodies showed that 16 and 20%, respectively, 
of the annexin II signals were in fractions 2 and 3 (Fig. 3). 
uPAR Associates with Caveolin 
GPI-linked proteins were reported to form stable complexes 
with cell surface molecules of distinct molecular sizes (14, 
22-29, 40, 50,  and 80 kD), caveolin (22-29 kD) being one 
of the major components (Lisanti et al., 1993). We reasoned 
that similar proteins may be associated with uPAR. M24met 
melanoma cells were surface biotinylated, lysed in NP-40 ly- 
sis buffer and immunoprecipitated with anti-uPAR antibod- 
ies.  Both the mouse monoclonal and the polyclonal rabbit 
anti-uPAR  antibodies  coprecipitated  uPAR  (Fig.  4,  aster- 
isks)  with  other  molecules  in  the  approximate molecular 
mass ranges of 22,  40,  65,  and 80 kD (Fig. 4),  suggesting 
that  uPAR  is contained  in  complexes similar to those de- 
Figure 3.  Western blotting of low-density Triton X-100 insoluble 
complexes from M24met cells. Cells were lysed and subjected to 
sucrose gradient centrifugation,  as described in the Materials and 
Methods section. The sucrose gradients were divided into fractions 
with fraction  1-6 containing  the 5-30% linear sucrose gradient, 
fraction 7 containing 40% sucrose, and fraction 8 the pellet. Equal 
amounts  of protein  from each  fraction  were  separated  by SDS- 
PAGE using a 5-15% acrylamide gradient gel and transferred to ni- 
trocellulose. The indicated proteins were detected in their appropri- 
ate molecular  mass range using specific antibodies against uPAR 
(55-60 kD), uPA (55 kD), caveolin (22 kD), annexin II  heavy chain 
(HC, 39 kD), and annexin II light chain (LC,  11 kD). 
Stahl and Mueller Localization of uPAR in Caveolae  339 Figure 4. Immunoprecipitation  of uPAR from surface biotinylated 
M24met cells. Immunoprecipitation of uPAR with either a uPAR 
specific  mouse monoclonal  antibody (A) or rabbit polyclonal  serum 
(C) resulted in the specific  coprecipitation  of surface  proteins in the 
molecular size range of  22, 40, 65, and 80 kD. The position of  uPAR 
is indicated  by asterisks. Immunoprecipitations  were specific, since 
preimmune mouse serum  (B)  or rabbit serum (D)  showed no 
signals. 
scribed for other GPI-linked proteins (Lisanti et al., 1993). 
The finding of multiple bands in the 22-29-kD range implied 
the uPAR associates with caveolin. To further test this hy- 
pothesis, we performed cross-linking experiments with Tri- 
ton X-100 insoluble proteins. To this end, M24met cells were 
extracted with 1%  Triton X-100 for 30 min on ice. Under 
these conditions, the caveolae remained in the insoluble frac- 
tion attached to the cytoskeleton (Lisanti et al., 1993).  The 
remaining insoluble proteins were cross-linked with DTSSP, 
a  water-soluble homobifunctional NHS-ester cross-linker, 
that can be cleaved under reducing conditions. A  second 
round of extraction was then performed with either 60 mM 
OGP  or  3%  Triton  X-l14.  Both  detergents  have  been 
reported to solubilize GPI-anchored proteins, as well as cav- 
eolin (Kurzchalia et al.,  1992;  Lisanti et al.,  1993).  The 
cross-linked complexes from  the second extraction were then 
subjected to immunoprecipitation with a polyclonal rabbit 
antibody  against  u_PAR. The  specifically bound  proteins 
were boiled in reducing sample buffer, separated by SDS- 
PAGE,  transferred  onto  a  nitrocellulose  membrane  and 
probed with the monoclonal antibody against caveolin. Un- 
der both detergent conditions, anti-uPAR antibodies copre- 
cipitated caveolin (Fig.  5),  although extraction with OGP 
seemed to be more efficient. These results demonstrate that 
in M24met cells, uPAR and caveolin exist in detergent in- 
soluble  complexes  in  close  spatial  association,  since  a 
distance of  12A  or  less  between the two  molecules can 
be deduced from the length of the cross-linker's spacer arm. 
Disruption of Caveolae by Nystatin Reduces 
CeU-Surf~e Bound uPA Activity 
The clustering of uPAR in caveolae suggested eaveolae as a 
compartment for cell  surface plasminogen activation. To 
study whether the structural integrity of caveolae is required 
for efficient  plasminogen activation, we used the cholesterol- 
binding drug nystatin. Nystatin selectively disrupts caveo- 
lae, but does not effect clathrin-coated pits, actin cables, or 
other  submembranous  structures  (Rothberg  et  al.,  1992; 
Lisanti et al.,  1993).  Treatment of M24met cells with 50 
/Lg/ml nystatin under serum-free conditions for up to 16 h 
had no effect  on the morphology or viability of  the cells (data 
not shown). In a cell free system, nystatin had no effect on 
the rate of plasmin generation by uPA or plasmin's ability to 
cleave the substrate peptide H-D-Val-Leu-Lys-p-nitroanilide. 
Furthermore, pretreatment of the cells with nystatin did not 
alter the amount of endogenous cell surface-bound uPA, as 
tested by indirect immunofluorescence, indicating that nysta- 
tin does not interfere with the binding of uPA to uPAR. 
To test the effect  of  nystatin  on cell surface plasmin genera- 
tion by uPA/uPAR,  M24met cells in 96-well  plates were 
treated with nystatin at 50 pg/ml for 1 h. Plasminogen and 
a  chromogenic substrate for plasmin, H-D-Val-Leu-Lys-p- 
nitroanilide, were added and the initial increase in reaction 
velocity was measured as AOD~ nm with measurements 
every 5 rain. The endogenously produced uPA on the cell 
surface of the M24met cells converted plasminogen into 
plasmin leading to a rapid and linear increase in the cleavage 
of the plasmin substrate over the first 30 rain of the reaction 
(Fig. 6). A polyclonal anti-uPA  antibody, as well as an in- 
hibiting monoclonal antibody against uPA, could block the 
reaction (Fig. 6 and Table I) demonstrating that uPA was the 
only significant  plasminogen activator in this system. Nysta- 
tin treatment of the cells resulted in a 50% reduction of the 
rate  of plasmin generation,  measured as  the  increase  in 
AOD405 um (Fig. 6), indicating that the structural integrity 
of the caveolae plays an important role for the effÉciency of 
plasminogen activation by surface-bound uPA. Our conten- 
tion that the observed reduction of the rate of plasmin gener- 
ation upon nystatin treatment was caused by the disruption 
of caveolae was supported by the effect of two other drugs 
that had also been reported to interfere with the morphology 
of caveolae. We used filipin, another cholesterol-binding an- 
tibiotic, that causes, like nystatin, an unclustering of GPI- 
linked molecules (Rothberg et al., 1990) and the protein ki- 
nase  C-activating  phorbol  ester  PMA,  which  had  been 
shown to markedly reduce the number of caveolae and to in- 
hibit potocytosis (Smart et al.,  1994).  Table I summarizes 
several experiments in which M24met cells were pretreated 
with nystatin, filipin, PMA,  or anti-uPA  antibodies. Both 
filipin and  PMA  treatment resulted  in  a  dose-dependent 
reduction in the rate of plasmin generation. 
Discussion 
The aim of our present study was to determine the subcellu- 
lar distribution of uPAR in a highly metastatic human mela- 
noma cell line. This cell line was previously shown to use 
nPA/uPAR for the degradation of  interstitial matrix and base- 
ment membrane (Montgomery et al.,  1993),  as well as for 
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tion  of caveolin  coimmuno- 
precipitated  with  uPAR. Ad- 
herent M24met cells were first 
extracted  with  1%  Triton 
X-100,  insoluble  proteins 
were  cross-linked  with 
DTSSP,  and  then  extracted 
with  either  OGP  or  Triton 
X-114.  Extracts  were  sub- 
jected  to  immunoprecipita- 
tion  with  anti-uPAR serum, 
separated  by SDS-PAGE un- 
der  reducing  conditions  and 
caveolin  was  detected  by 
Western blotting with an anti- 
caveolin  mAb.  OGP  lysates 
are shown in lane A and Triton 
X-114 lysates in lane B. Note 
that the signal ~60-kD corre- 
sponds to the heavy chain of 
the antibody used  for immu- 
noprecipitation. 
invasion through reconstituted basement membrane and for 
haptotaetic migration (Stahl and Mueller,  1994).  Here, we 
demonstrate that uPAR on M24met human melanoma cells 
is localized in caveolae and that caveolae provide an environ- 
ment allowing for enhanced cell surface plasminogen acti- 
vation. 
Immunoelectron microscopy indicated that anti-uPAR an- 
tibodies localized the  receptor on the  surface of M24met 
cells  in  membrane invaginations  which  were  observed in 
clusters along the plasma membrane and appear to be caveo- 
lae. When visualized by indirect immunofluorescence, anti- 
uPAR antibodies stained these cells in a punetated pattern, 
which  completely  colocalized  with  the  signal  from  anti- 
80 
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40- 
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Figure 6. Inhibition of plasminogen activation by nystatin. Plasmin 
generation by endogenously produced cell surface-bound  uPA on 
untreated  M24met  human  melanoma cells  ([]) was compared  to 
cells treated with either 50 ttg/ml nystatin (zx) or 0.2 mg/ml of an 
inhibiting mouse anti-uPA mAb (o). Plasmin generation was mea- 
sured  as AOD4o5 after the addition  of plasminogen  (2 tiM)  and 
H-D-Val-Leu-Lys-p-nitroanilide (2.2 mM) to the cells. Data points 
represent the mean of 8 wells. The experiment was performed three 
times with similar results. 
Table L  Inhibition of Cell Surface Plasmin Generation 
by Drugs Interfering  with the Morphology of Caveolae 
Pretreatment  Concentration  Inhibition 
% 
Nystatin  25 /~g/ml  42.6 
50 t,g/ml  53.5 
Filipin  5 ttg/ml  41.5 
20 #g/ml  42.8 
PMA  0.1 /tM  10.4 
1 #M  42.1 
Rabbit polyclonal  0.2 mg/ml  86.2 
anti-uPA 
Mouse monoclonal  0.2 mg/ml  99.0 
anti-uPA 
Chromogenic plasmin assays were performed, as described in the Materials 
and Methods section. The rate of plasmin generation was calculated for each 
treatment using linear regression, as shown in Fig. 6. 
caveolin antibodies. Based on these observations of native, 
as well as fixed and saponin permeabilized cells,  we con- 
clude that M24met human melanoma cells possess abundant 
plasmalemmal caveolae and that uPAR is localized in these 
caveolae. This is, to our knowledge, the first description of 
eaveolae on neuro-ectodermal cells suggesting a general im- 
portance of these organelles on different types of cells, in- 
cluding tumor cells of neuro-ectodermal origin. The local- 
ization  of  uPAR  in  such  plasmalemmal  caveolae  is  in 
agreement with the previously described subcellular distri- 
bution of other GPI-linked proteins on cultured cells. In this 
regard,  endogenous  GPI-linked proteins  (Rothberg et al., 
1990; Ying et al.,  1992), as well as GPI-linked proteins ex- 
pressed after eDNA transfection (Ying et al.,  1992;  Keller 
et al., 1992) were demonstrated to be preferentially localized 
in caveolae. 
In addition  to the localization of uPAR in caveolae, im- 
munogold staining for uPAR also labeled sporadically, but 
consistendy, coated pits and cellular processes of M24met 
cells (data not shown).  The localization of some uPAR in 
coated pits is consistent with previous work (Nykjaer et al., 
1992; Li et al.,  1994) that demonstrated that the oL2 macro- 
globulin  receptor/low  density  lipoprotein  receptor-related 
protein mediates the internalization of uPA-plasminogen ac- 
tivator inhibitor complexes bound to uPAR, a process occur- 
ring most likely in clathrin-coated pits. 
Occasionally,  immunofluorescence  demonstrated  uPAR 
and  caveolin  on  M24met  cells  concentrated  in  areas  of 
cell-cell contacts or membrane ruffles. Similarly, uPAR was 
described previously in  areas of cell-cell contact  for HT 
1080  cells (P611iinen et al.,  1987)  and rhabdomyosarcoma 
cells (Myfhiinen et al.,  1993). In contrast, we found no evi- 
dence for a preferential localization of uPAR at the interface 
between cell and substrate or for the presence of the receptor 
in  sites of focal contacts.  In this  regard our observations 
differ from the distribution of uPAR on HT  1080  fibrosar- 
coma cells and cultured fibroblasts on which uPAR was de- 
scribed to colocalize with vinculin in focal contacts (Pfllii- 
nen et al.,  1988;  Hebert and Baker,  1988).  Generally, the 
distribution of uPAR on M24met melanoma cells resembles 
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on amnion WISH cells (Busso et al., 1994) and the granular 
pattern that was described for MCF7 breast carcinoma cells 
(Zhang et al.,  1993). 
The localization of uPAR in caveolae was further sup- 
ported by our biochemical analysis of low density, detergent 
insoluble complexes that were previously shown to contain 
membrane fractions highly enriched for caveolae (Sargia- 
como et al., 1993). We demonstrated uPAR, its ligand uPA, 
and caveolin by immunoblotting almost exclusively in low 
density, Triton X-100 insoluble fractions of M24met lysates. 
uPAR  exhibited a  somewhat broader  density distribution 
than uPA and caveolin, with 93 % of the uPAR signal in the 
ranges of 9-22%  sucrose, and 91% of the uPA and 99% of 
the caveolin signal, respectively, in the ranges of 9-17.5 su- 
crose. Thus, ~70%  of uPAR is colocalized with caveolin, 
while a subpopulation of uPAR appears to be associated with 
neither uPA nor caveolin. This distribution might suggest 
that under certain thus far undefined conditions, GPI-linked 
molecules exist in Triton X-100 insoluble, low density com- 
plexes that differ from caveolin-coated caveolae. 
After surface biotinylation  of intact living cells, anti-uPAR 
antibodies coprecipitated a molecule with a similar molecu- 
lar weight as caveolin. A close spatial association between 
uPAR and caveolin was further suggested by their coprecipi- 
tation from the Triton X-100 insoluble fraction of M24met 
cells after cross-linking. The presence of uPAR in low den- 
sity, detergent insoluble complexes and the spatial associa- 
tion between uPAR and caveolin indicate that uPAR is local- 
ized in caveolae in the absence of cross-linking antibodies. 
It was suggested recently (Mayor et al.,  1994)  that GPI- 
linked proteins cluster in caveolae only as a result of physio- 
logically or experimentally induced cross-linking. Accord- 
ingly, the presence of uPAR in caveolae on our metastatic 
melanoma cell line may imply that the receptor is cross- 
linked as a consequence of uPA binding and/or interaction 
with vitronectin (Wei et al.,  1994) or other components of 
the extraceUular  matrix. 
GPI-linked proteins have been demonstrated to interact 
with nonreceptor tyrosine kinases of the src family (Stefa- 
nova et al.,  1991; Thomas and Samelson,  1992;  Shenoy- 
Scaria et al., 1992) suggesting a role for GPI-linked proteins 
in signal transduction processes. Based on the analysis of  low 
density detergent insoluble complexes, it has been proposed 
that the src substrate caveolin may function as a transmem- 
brane adaptor protein that couples GPI-anchored proteins 
with cytoplasmatic signaling molecules (Sargiacomo et al., 
1993).  Catalytically inactive uPA  can induce cellular re- 
sponses, such as proliferation and migration (Kirchheimer et 
al.,  1989;  Odekon et al.,  1992;  Gyetko et al.,  1994;  Stahl 
and Mueller, 1994) implicating uPAR as a molecule involved 
in signal transduction. The mechanism by which GPI-linked 
proteins, such as uPAR, could activate cells is presently un- 
known. The close spatial association between uPAR and cav- 
eolin described here,  suggests that caveolin could be  in- 
volved in signal transduction mediated by uPAR. 
Both uPAR and its ligand, uPA, were detected exclusively 
in the low density, Triton X-100 insoluble fraction of mela- 
noma cell lysates, which suggests that caveolae may serve as 
a specialized compartment for pericellular plasminogen acti- 
vation. The structural integrity of caveolae depends on cho- 
lesterol (Rothberg et al., 1992).  Cholesterol-binding drugs, 
such as nystatin, have been shown to disperse both the stri- 
ated coat of caveolae and clustered GPI-linked folate recep- 
tors (Rothberg et al., 1992) without affecting submembrane- 
ous structures. Treatment of M24met cells with nystatin and 
other drugs interfering with the structure of caveolae re- 
duced the rate of cell surface plasmin generation up to 50% 
indicating that the clustering of uPAR and uPA in caveolae 
enhances cell surface plasminogen activation. This inhibi- 
tion was not due to a direct effect of the drugs on the catalytic 
activity of  uPA or plasmin or on the binding of uPA to uPAR. 
The  effect was  also  not restricted to  cholesterol-binding 
drugs, since PMA, which reduces the number of caveolae 
probably by activating protein kinase C, caused also a reduc- 
tion in the rate of plasmin generation. The contention that 
uPAR enhances uP?/s  catalytic activity at least partly by 
localizing it in caveolae is strengthened by the recent finding 
that recombinant uPA linked with a GPI-anchor to the cell 
membrane, and thus likely clustered in caveolae, shows al- 
most the same rate of enhanced catalytic activity as uPA 
bound to uPAR (Lee et al.,  1994). 
Caveolae may allow for enhanced cell surface plasmino- 
gen activation by clustering uPAR/uPA  and other compo- 
nents of the fibrinolytic system, thus providing a favorable 
environment for protease cooperation. In this regard, it may 
be significant that we find annexin II, which has been de- 
scribed as a receptor for plasminogen and tissue type plas- 
minogen activator (Hajjar et al.,  1994;  Cesarman et al., 
1994),  also in the low density Triton X-100 insoluble frac- 
tion  of M24met  melanoma cells.  The  ganglioside GM1, 
which is another plasminogen-binding molecule (Miles et 
al., 1989), is also localized in caveolae (Parton, 1994). Fur- 
thermore,  a  close  association of uPA-  and plasminogen- 
receptors  has  been  suggested  (Zhang  et  al.,  1993) by 
colocalization of anti-uPAR antibodies and biotinylated  plas- 
minogen on MCF7 cells. 
In summary, we demonstrate here that the GPI-anchored 
protease receptor uPAR on a metastatic human melanoma 
cell line is localized in caveolae and that the structural in- 
tegrity of caveolae is a prerequisite for efficient cell surface 
plasminogen activation, thus implicating caveolae as a cell 
membrane specialization involved in the regulation of cell 
activation and pericellular proteolysis. 
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